We sat down with Ha Kung Wong, an intellectual property law attorney and partner at Venable Fitzpatrick in New York and April Breyer Menon, an expert on biosimilar patent law and founder of April Breyer Consulting in Chicago, Illinois, to discuss potential bills to improve biosimilar uptake and their chances for passage.
Despite the United States having had a biosimilar pathway for a decade now, the industry has launched just 17 biosimilars on the market, well behind the pace in Europe and India. Several pieces of legislation have been introduced in Congress to help boost uptake, generate savings for payers and patients, and increase biosimilar access. However, not every bill is likely to become a law, as politics and money can often get in the way.
We sat down with Ha Kung Wong, an intellectual property law attorney and partner at Venable Fitzpatrick in New York and April Breyer Menon, an expert on biosimilar patent law and founder of April Breyer Consulting in Chicago, Illinois, to discuss potential bills to improve biosimilar uptake and their chances for passage.
To learn more about Venable Fitzpatrick, visit venable.com.
To learn more about the Biologic Patent Transparency Act, visit congress.gov.
To learn more about the Affordable and Safe Prescription Drug Importation Act, visit congress.gov.
To learn more about the BIOSIM Act, visit congress.gov.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
How Health Policy Can Impact Adoption for Adalimumab Biosimilars
September 25th 2022In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.